<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25614613</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>06</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>08</Month>
            <Day>31</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2393</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>108</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>QJM : monthly journal of the Association of Physicians</Title>
                <ISOAbbreviation>QJM</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The role of biologics in treatment of connective tissue disease-associated interstitial lung disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>683-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/qjmed/hcv007</ELocationID>
            <Abstract>
                <AbstractText>With an increased understanding of the molecular pathways of inflammation and autoimmunity, the development of targeted biological agents has revolutionized the management of connective tissue diseases (CTDs). There has been an explosion in the development of these drugs in the last decade, targeting diseases in diverse fields including: allergic disorders, oncology, neuroinflammatory disorders, inflammatory bowel disease, macular degeneration and CTDs. In this last field, commonly applied biologics fall into two categories: cytokine inhibitors and lymphocyte-targeted therapies. The former group includes the antitumour necrosis factor alpha (TNF-α), anti-interleukin (IL)-6 receptor monoclonal antibodies and IL-1 receptor antagonists, whilst the latter encompasses the anti-CD20, B-cell depleting, monoclonal antibody (mAb), Rituximab and the anti-T-cell activation agent, Abatacept. This review will examine our developing experience in the use of these agents in the treatment of CTD-related interstitial lung diseases, with a particular focus on B-cell depletion. </AbstractText>
                <CopyrightInformation>© The Author 2015. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sharp</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol Interstitial Lung Disease Unit, North Bristol NHS Trust, Brunel Building, Southmead Hospital, Bristol BS10 5NB, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dodds</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol Interstitial Lung Disease Unit, North Bristol NHS Trust, Brunel Building, Southmead Hospital, Bristol BS10 5NB, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mayers</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol Interstitial Lung Disease Unit, North Bristol NHS Trust, Brunel Building, Southmead Hospital, Bristol BS10 5NB, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Millar</LastName>
                    <ForeName>A B</ForeName>
                    <Initials>AB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol Interstitial Lung Disease Unit, North Bristol NHS Trust, Brunel Building, Southmead Hospital, Bristol BS10 5NB, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gunawardena</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol Interstitial Lung Disease Unit, North Bristol NHS Trust, Brunel Building, Southmead Hospital, Bristol BS10 5NB, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adamali</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol Interstitial Lung Disease Unit, North Bristol NHS Trust, Brunel Building, Southmead Hospital, Bristol BS10 5NB, UK Huzaifa.Adamali@nbt.nhs.uk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>QJM</MedlineTA>
            <NlmUniqueID>9438285</NlmUniqueID>
            <ISSNLinking>1460-2393</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001688">Biological Products</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>4F4X42SYQ6</RegistryNumber>
                <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003240" MajorTopicYN="N">Connective Tissue Diseases</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25614613</ArticleId>
            <ArticleId IdType="pii">hcv007</ArticleId>
            <ArticleId IdType="doi">10.1093/qjmed/hcv007</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>